Key Discussion Points:

• Key lessons from the pandemic & the fundamental changes this event has wrought upon your industry and organisation
• Key challenges for the industry in 2021
• Addressing the rising demand for generics in the international markets
• Indian companies have invested a lot in research capabilities. Strengthening this critical area
• Indian and global pharma companies collaborating to bring greater benefits to patients, especially in critical illnesses
• The power of digital technologies is most effective in the research and production of medicine. Discussion on technology investment plans going ahead

• Deepak Sapra CEO, API & Services, Dr. Reddy’s
• Vivek V. Kamath Managing Director & General Manager, Specialty Care, Pharmaceuticals, Abbott India
• Ramesh Swaminathan CFO and Head Corporate Affairs, Lupin
• Venugopal Vijayendran President India Business, Intas Pharma
• Dr. Vikas Gupta India Business Head, Cipla
• Rishabh Bindlish Managing Director, India Life Sciences and Global Generics Lead, Accenture
• Alokesh Bhattacharyya (Moderator) Senior Editor, The Economic Times